VKORC1 Inhibitors
1 drugsAbout VKORC1
Vitamin K epoxide reductase complex subunit 1 (VKORC1) is an enzyme in the vitamin K cycle, reducing vitamin K to its active form, essential for synthesizing coagulation factors.
VKORC1 is a key target for anticoagulant therapies in cardiovascular disease, though no genetic evidence directly links it to specific diseases.
VKORC1 is targeted by one FDA-approved drug, JANTOVEN, a small molecule used in cardiovascular applications since 2003.
Top VKORC1 Drugs
UPSHER SMITH LABS is the only company with an approved drug targeting VKORC1.
The lack of competition suggests high barriers to entry or limited perceived market opportunity.
VKORC1 Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets VKORC1, using small molecule modality.
Exploring alternative modalities like antibodies or peptides could offer differentiation and new IP.
VKORC1 Clinical Trials 170 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on VKORC1. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 78 | 70 | 2 | 6 | 97% |
| Phase 2 | 19 | 13 | 5 | 1 | 72% |
| Phase 3 | 31 | 22 | 4 | 5 | 85% |
| Phase 4 | 42 | 26 | 6 | 10 | 81% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
VKORC1 Drug Approval Timeline (2003 - 2003)
JANTOVEN was first approved in 2003 and remains the only approved drug targeting VKORC1.
The stagnant approval timeline indicates a mature market with limited innovation in VKORC1-targeted therapies.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 118 (54 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on VKORC1. A trial counts if an approved drug acting on VKORC1 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.